Reed Jobs Prefers Discussing Cancer Cures Over His Famous Last Name
Reed Jobs, son of Apple co-founder Steve Jobs, is rapidly accelerating the mission of his oncology-focused venture firm, Yosemite, aiming to revolutionize cancer treatment through a blend of early-stage academic
Reed Jobs, son of Apple co-founder Steve Jobs, is rapidly accelerating the mission of his oncology-focused venture firm, Yosemite, aiming to revolutionize cancer treatment through a blend of early-stage academic research, strategic investment, and deep integration of artificial intelligence. Three years after its inception, Yosemite has grown to a 17-person team and is actively raising its second fund, targeting $350 million, amidst a transformed biotech landscape. Jobs emphasizes that the firm's ambition to "make" new cures, rather than just find them, is moving faster than even he anticipated, largely fueled by AI's profound impact on drug discovery and clinical trial efficiency.
Yosemite's Accelerated Growth and AI Integration
When Jobs last discussed Yosemite at TechCrunch Disrupt three years prior, the firm was nascent, and the biotech sector was recovering from a post-pandemic slump. Today, the landscape is vibrant, marked by a surge in pharmaceutical acquisitions and a critical juncture where numerous blockbuster drugs are losing patent protection, opening vast new opportunities. Jobs highlights AI as a "huge part" of Yosemite's strategy, transforming it from a mere curiosity into a foundational tool for accelerating research.
AI's influence is particularly evident in overcoming long-standing challenges in drug development. Jobs points to its role in targeting previously "undruggable" proteins like KRAS, a major cancer-driving gene. AI has allowed scientists to identify cryptic pockets and novel ways to block mutations, leading to breakthroughs like Revolution Medicines doubling pancreatic cancer survival rates. Yosemite is also pursuing the "Achilles' heel" of cancer, the p53 tumor suppressor gene, with three different companies employing various AI-assisted strategies.
Beyond discovery, AI is poised to drastically cut costs and time in clinical trials, which represent the largest financial and temporal sink in drug development. By enabling "synthetic control arms" – computer-generated comparison groups from existing patient data – AI can halve patient recruitment needs and significantly expedite trials, a development the FDA is actively supporting.
Strategic Investments and Unique Operating Model
Yosemite's investment model is distinct: approximately one-third of its fund is dedicated to building companies from scratch, often collaborating with academic institutions like Yale, Berkeley, and Stanford. The remaining capital supports external companies aligned with their vision. Crucially, 2.5% of the fund's assets under management, plus $1 million annually from management fees, are allocated to a donor-advised fund, providing no-strings-attached philanthropic grants to de-risk early-stage academic ideas.
The firm's portfolio, now close to 25 companies, includes notable successes like Azalea, which evolved from a grant to Jennifer Doudna's lab and is now in clinical trials, and Quarry, co-founded with Craig Crews, exploring induced proximity therapeutics. Jobs also highlights Tune Therapeutics, a leader in epigenetic editing for Hepatitis B, and Histosonics, a device company utilizing histotripsy for non-invasive liver tumor destruction. While two companies have failed scientifically, Jobs notes this is an expected outcome for early-stage, high-risk ventures.
Navigating the Biotech Landscape and Future Outlook
Jobs observes a significant shift in biotech investor conservatism since 2023. Lower interest rates, combined with pharmaceutical companies sitting on record cash reserves and facing massive patent cliffs, have spurred an "acquisitive spree." This has led to major exits, such as Eli Lilly's $7 billion acquisition of Kelonia, signaling renewed confidence in the sector.
Despite these positive trends, Jobs remains concerned about proposed federal cuts to NIH funding. While bipartisan rejection has so far prevented drastic reductions, he advocates for an increase to $100 billion, noting that funding has shrunk relative to inflation over the past decade.
For aspiring founders, Jobs advises understanding pharma's shifting priorities and emphasizes Yosemite's open-door policy, reviewing grants and companies without bias for CVs or titles. He acknowledges the importance of storytelling in securing funding, often separating the academic founder from a professional CEO tasked with raising capital and communicating the company's vision.
Jobs expresses surprise at the rapid acceleration of progress in oncology, citing the emergence of trillion-dollar pharmaceutical companies driven by breakthroughs like GLP-1s, which are also showing potential protective effects against neurodegenerative disease and cancer. This has brought "undruggable" oncogenes like KRAS, Myc, beta-catenin, and p53 "within reach," marking a pivotal and empowering moment for cancer research. While personally interested in longevity, Jobs remains cautious, emphasizing the lack of a "grand unified theory of aging" and the individualized nature of the problem.
FAQ
Q: What is Yosemite's core mission and unique approach? A: Yosemite is an oncology-focused venture firm aiming to "make" new cures for cancer by building companies from early academic research. It uses a hybrid model of venture capital and philanthropy, providing no-strings-attached grants to de-risk nascent scientific ideas, alongside traditional investments.
Q: How is AI impacting cancer drug development and clinical trials at Yosemite? A: AI is accelerating drug discovery by performing grunt work incredibly fast, finding previously inaccessible drug targets like cryptic pockets on proteins such as KRAS, and identifying new ways to block them. In clinical trials, AI can create "synthetic control arms" from existing patient data, reducing the need for patient recruitment and significantly speeding up development timelines.
Q: What is Reed Jobs's view on the current biotech investment climate? A: Jobs believes the biotech investment climate has improved significantly since 2023. Lower interest rates, a wave of expiring drug patents, and pharma companies with substantial cash reserves have led to an increase in acquisitions and major exits, creating a more favorable environment for innovation.
Related articles
JPMorgan Chase Taps Seattle for Critical AI Control Layer Development
Global financial giant JPMorgan Chase is making a significant strategic investment in Seattle, establishing a new AI software infrastructure team. This pivotal group will build an "AI control layer" to manage the bank's AI operations, aiming to control costs, protect intellectual property, and prevent vendor lock-in.
The Motorola Edge 70 Max is all about power: Android — Key Details
Motorola has launched its new flagship, the Edge 70 Max, designed for power users with a massive 7100mAh silicon-carbon battery and 25W Qi2 wireless charging. It’s the first Android phone since the Pixel 10 Pro XL to support full 25W Qi2, surpassing other Qi2-enabled Androids capped at 15W. The device also offers 90W wired charging and a Snapdragon 8 Gen 5 chip.
DeepMind CEO calls for independent body to regulate frontier AI
DeepMind CEO Demis Hassabis has proposed an independent standards body, modeled after FINRA, to regulate frontier AI models. The body would test advanced AI systems and develop best practices for their release, initially on a voluntary basis before potentially becoming mandatory. This initiative aims to provide technically focused, adaptable oversight to the rapidly evolving field of AI.
OnePlus is reportedly bailing on the US: Oppo — Key Details
OnePlus, and parent company Oppo, are reportedly exiting the US and European markets, with an announcement due shortly. This follows months of rumors and signals a major shift in the Western smartphone landscape.
startups: The web is now mostly bots. Cloudflare is rebuilding its
Cloudflare has launched Precursor, a new defense system, in response to bots now generating over 57% of all web traffic. Precursor monitors entire user sessions to distinguish humans from sophisticated bots, moving beyond traditional single-check methods. This initiative is part of a broader strategy to classify and manage AI agents, control content reuse, and rebuild the web's foundational infrastructure for a machine-dominated internet.
industry: ACRouter picks the smartest AI model per task, beating
A groundbreaking open-source framework, ACRouter, dynamically selects the most capable and cost-effective AI model for any given task, demonstrating a 2.6x cost reduction over Opus-only setups while maintaining performance. It learns and adapts in real-time, addressing limitations of static routing.